--- title: "Checkpoint Blockade: Taking a Brake Off a T Cell" description: "Inhibitory receptors that normally limit T-cell responses are used by tumours to avoid killing, and antibodies against those receptors restore it in a minority of patients. This stop covers the mechan" canonical: https://lightmysky.com/learn/science/checkpoint-blockade-taking-a-brake-off-a-t-cell-mt_f9P4LlaBGb source: https://lightmysky.com/learn/science/checkpoint-blockade-taking-a-brake-off-a-t-cell-mt_f9P4LlaBGb.md retrieved: 2026-09-12 --- > **Agent view.** This is the Markdown twin of the page, for tools and assistants. > When to use this site, and the call that answers each job: https://lightmysky.com/agent-instructions.md > API description (OpenAPI 3.1): https://lightmysky.com/openapi.json · Authentication: https://lightmysky.com/auth.md > Pricing: https://lightmysky.com/pricing.md · Catalog: https://lightmysky.com/llms.txt · Full catalog: https://lightmysky.com/llms-full.txt > Every machine-readable file on this domain: https://lightmysky.com/.well-known/ai-catalog.json > Ask for Markdown with `Accept: text/markdown`, a `.md` address, or `?mode=agent`. # Checkpoint Blockade: Taking a Brake Off a T Cell Inhibitory receptors that normally limit T-cell responses are used by tumours to avoid killing, and antibodies against those receptors restore it in a minority of patients. This stop covers the mechanism, the markers that predict response, and the autoimmune cost. Subject: Science · Area: The Human Body · Ages 22 to 24 Page: https://lightmysky.com/learn/science/checkpoint-blockade-taking-a-brake-off-a-t-cell-mt_f9P4LlaBGb ## Ready when they can - Explain how blocking CTLA-4 and blocking PD-1 act at different points of a T-cell response - Interpret mutational burden and antigen presentation status as predictors of response - Relate immune-related adverse events to the mechanism of the drug rather than to off-target effects ## Lesson: Releasing T cells to fight tumours Some tumours survive by hiding from the T cells built to destroy them. Helpers carry CD4 and coordinate, killers carry CD8 and destroy abnormal cells directly, and regulators calm things so healthy tissue is spared. A naive cell switches on only when it sees its antigen on an MHC molecule plus a second costimulatory push. This is the cell mediated arm of immunity: T cells acting against abnormal cells themselves. You place the two brakes. CTLA-4 acts early during priming by outcompeting the accelerator CD28 and raising the activation threshold. PD-1 acts later, quieting T cells that already reached the tissue. Blocking CTLA-4 releases the early pool, while blocking PD-1 frees the cells already at the fight. **Example.** You compare two patients. One tumour carries many mutations, so its odd neoantigens look foreign and the response is strong once brakes lift. The other hid its presentation machinery, so it stays invisible even with brakes off. You predict the first gains and the second gains little. You read side effects as mechanism, not poisoning. Released T cells also strike gut, skin, or glands, so inflamed organs follow from the same release that fights the tumour. And you remember the drugs free existing held back cells rather than creating new ones from nothing. **Recap.** You match the drug to the brake point, you predict response from burden plus presentation, and you treat side effects as on target release. ## Practice 8 questions on this page, each with its working shown. ## Needs first - [Adaptive Immunity: Antigen Presentation and T-Cell Selection](https://lightmysky.com/learn/science/adaptive-immunity-antigen-presentation-and-t-cell-selection-mt_8hTGqrnqGY) ## Opens up - [Engineered Cell Therapy: Receptor Design, Manufacture and Toxicity](https://lightmysky.com/learn/science/engineered-cell-therapy-receptor-design-manufacture-and-toxicity-mt_e15TOnMMwL)